FDA rejects Ocular Therapeutix post-operative eye pain treatment

(Reuters) - Drug developer Ocular Therapeutix Inc said the U.S. Food and Drug Administration had denied approval for its treatment for post-operative eye pain. The company said on Monday that the FDA raised concerns related to its manufacturing process after an inspection of its facility. (Reporting by Dipika Jain in Bengaluru; Editing by Kirti Pandey)